Request for a sample of this research report @ https://www.coherentmarketinsights.com/insight/request-sample/1774
Market Trends:
Viral vector-based gene therapy is gaining immense popularity in the market owing to its high efficiency. Retroviruses and lentiviruses are commonly used viral vectors to integrate the functional gene into the host cell genome. Chinese Hamster Ovary (CHO) cells are extensively utilized bioreactors for commercial-scale manufacturing of viral vectors for gene therapies.
Leading players are also focusing on developing non-viral gene therapies to overcome several challenges associated with viral vectors such as immunogenicity, insertional mutagenesis, and luggage size restrictions. For instance, CRISPR/Cas9 gene editing is a promising non-viral approach for correcting mutations associated with genetic disorders.
Market Opportunities:
The global gene therapy market was valued at US$ 9 billion in 2023 and is anticipated to witness a CAGR of 19.3% during the forecast period of 2024-2031. Gene therapy offers a potentially curative approach for various genetic disorders by correcting defective genes or replacing missing genes. Two major market opportunities in the rapidly growing gene therapy market are discussed below.
Viral vector gene therapy accounted for the largest share of the global gene therapy market in 2023. Within viral vectors, retroviral vectors dominated the market owing to their ability to efficiently and stably integrate transgenes into the genomes of dividing cells. Lentiviral vectors are also gaining popularity due to their ability to transduce both dividing and non-dividing cells.
The in vivo delivery method held the largest market share in 2023 due to the advantages it offers over ex vivo delivery methods. In vivo gene therapy involves direct administration of vector materials into target tissues and enables broad tissue distribution through systemic delivery methods like intravenous injections. This approach obviates the need for cell isolation, ex vivo manipulation and transplantation required for ex vivo delivery.
To Purchase a Comprehensive Report Analysis @ https://www.coherentmarketinsights.com/insight/buy-now/1774
Key Market Takeaways
The global gene therapy market is anticipated to witness a CAGR of 19.3% during the forecast period of 2024-2031, driven by the ability of gene therapy to provide long-term cure and prevent the progression of diseases.
On the basis of vector, viral vectors segment dominated the market in 2023 led by retroviral and lentiviral segments.
Based on delivery method, the in vivo segment held the largest share in 2023 due to advantages over ex vivo delivery.
In terms of indication, cancer was the leading segment in 2023 owing to rising cancer incidence and the curative potential of gene therapy for cancer.
Regionally, North America dominated the global market in 2023 owing to higher adoption and presence of major market players in the region.
Key Players Insights
• Merck KGaA
• REGENXBIO, Inc.
• Oxford BioMedica plc
• Dimension Therapeutics, Inc.
• Bristol-Myers Squibb Company
• SANOFI
Recent Developments
In May 2023, the
FDA approved Vyjuvek, a herpes-simplex virus type 1 (HSV-1) vector-based gene
therapy, for the treatment of wounds in patients 6 months and older with
dystrophic epidermolysis bullosa (DEB) and mutation(s) in the collagen type VII
alpha 1 chain (COL7A1) gene.
In April 2023, REGENXBIO Inc. announced that the FDA has given fast track
designation to RGX-202, a possible one-time gene therapy for the treatment of
Duchenne muscular dystrophy (Duchenne).
Request Customization @ https://www.coherentmarketinsights.com/insight/request-customization/1774
About Us:
Coherent Market Insights is a global market intelligence and consulting
organization that provides syndicated research reports, customized research
reports, and consulting services. We are known for our actionable insights and
authentic reports in various domains including aerospace and defense,
agriculture, food and beverages, automotive, chemicals and materials, and
virtually all domains and an exhaustive list of sub-domains under the sun. We
create value for clients through our highly reliable and accurate reports. We
are also committed in playing a leading role in offering insights in various
sectors post-COVID-19 and continue to deliver measurable, sustainable results
for our clients.
Contact Us:
Mr. Shah
Senior Client Partner – Business Development
Coherent Market Insights
Phone:
US: +1-650-918-5898
UK: +44-020-8133-4027
AUS: +61-2-4786-0457
India: +91-848-285-0837
Email: sales@coherentmarketinsights.com
